Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.76% and 1.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.
United Therapeutics (UTHR) delivered earnings and revenue surprises of 11.72% and 1.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.
Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.
Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.
June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -9.52% and 7.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.